23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Ultragenyx Pharmaceutical Inc. › 2025-2026

Ultragenyx Pharmaceutical Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Ultragenyx Pharmaceutical Inc.’s Form 8-K, filed May 18, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 6Ballot items
  • 318Asset managers, any item
  • 1,957Fund votes
  • May 14, 2026Meeting date

Results at a glance

Meeting of May 14, 2026: 6 items on Ultragenyx Pharmaceutical Inc.’s Form 8-K, filed May 18, 2026: 2 approved · 4 passed (calculated).

Dissent

Notable dissent: 1 director (10.6% against); 1 other board item (31.1% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Activist investors: Nantahala Capital (13F, 2.3%, as of September 30, 2026)

Explore Ultragenyx Pharmaceutical Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Ultragenyx Pharmaceutical Inc.

These tallies are Ultragenyx Pharmaceutical Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 18, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Ultragenyx Pharmaceutical Inc. — official shareholder meeting results, meeting held May 14, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Emil D. Kakkis, M.D., Ph.D. 72,517,613---- 1,056,88511,211,890 99%Passed (calculated)—
Elect Director: Shehnaaz Suliman, M.D. 65,801,638---- 7,772,86011,211,890 89%Passed (calculated)—
Elect Director: Daniel G. Welch 66,301,426---- 7,273,07211,211,890 90%Passed (calculated)—
Approval of the Third A&R 2023 Plan At the Annual Meeting, the Company's stockholders approved the Third A&R 2023 Plan. The votes on Proposal 2 were 50,659,15022,888,60026,748 --11,211,890 69%Approved—
Ratification of Selection of Independent Registered Accounting Firm At the Annual Meeting, the Company's stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal yea 84,551,399221,80213,187 ---- 99.7%Approved—
4. Advisory (Non-Binding) Vote to Approve Executive Compensation At the Annual Meeting, the Company's stockholders voted, on an advisory basis, in favor of a resolution approving the compensation the Company pays to its "named executive officers" as described 70,945,2772,594,51734,704 --11,211,890 96%Passed (calculated)—

Source: Ultragenyx Pharmaceutical Inc., Form 8-K, filed with the SEC on May 18, 2026 — read the filing on EDGAR.

How asset managers voted at the Ultragenyx Pharmaceutical Inc. 2025-2026 meeting

318 asset managers disclosed a vote on at least one Ultragenyx Pharmaceutical Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Daniel G. Welch

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%
FOR: 66,301,426WITHHELD: 7,273,072
Details: description as filed, official tally, votes by 84 asset managers

Description as filed by funds: Nominees: Daniel G. Welch

Ultragenyx Pharmaceutical Inc.’s own tally for this item (“Elect Director: Daniel G. Welch”): 66,301,426 for, 7,273,072 withheld, per its Form 8-K filed May 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 90% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 84 asset managers below reported 23,901,615 for, 1,865,849 withheld, 15 abstained.

FOR
FOR: 23,901,615ABSTAIN: 15WITHHOLD: 1,865,849
Largest asset managers voting on “Nominees: Daniel G. Welch” at Ultragenyx Pharmaceutical Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard9,494,9180 151,238,724Mixed
State Street3,369,1360 0134For
BlackRock2,754,3220 00For
Fidelity2,202,3860 0278,332Mixed
T. Rowe Price728,2820 00For
TOUCHSTONE FUNDS GROUP TRUST660,3160 00For
TIAA622,8500 00For
AQR580,9410 00For
Charles Schwab557,6160 00For
John Hancock410,0480 00For
AMG FUNDS288,5380 00For
MFS257,0570 00For
Invesco221,5010 00For
Nationwide113,7880 00For
FRANKLIN STRATEGIC SERIES108,0670 00For
ALGER FUNDS107,1430 00For
Russell Investments96,6460 00For
MASTER INVESTMENT PORTFOLIO94,3620 00For
Goldman Sachs82,2500 03,675For
Harbor ETF Trust83,6560 00For
RBB FUND, INC.80,2810 00For
Direxion Shares ETF Trust76,7850 00For
ProShares76,5530 00For
Delaware/Macquarie00 076,531Withhold
Bridge Builder Trust61,3200 00For

Showing the 25 largest of 84 asset managers. All 84 are in the interactive database (link above).

Elect Director: Emil D. Kakkis, M.D., Ph.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 72,517,613WITHHELD: 1,056,885
Details: description as filed, official tally, votes by 84 asset managers

Description as filed by funds: Nominees: Emil D. Kakkis, M.D., Ph.D.

Ultragenyx Pharmaceutical Inc.’s own tally for this item (“Elect Director: Emil D. Kakkis, M.D., Ph.D.”): 72,517,613 for, 1,056,885 withheld, per its Form 8-K filed May 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 84 asset managers below reported 25,451,671 for, 315,806 withheld, 2 abstained.

FOR
FOR: 25,451,671ABSTAIN: 2WITHHOLD: 315,806
Largest asset managers voting on “Nominees: Emil D. Kakkis, M.D., Ph.D.” at Ultragenyx Pharmaceutical Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard10,725,4340 28,221For
State Street3,364,2030 05,067For
BlackRock2,754,3220 00For
Fidelity2,202,3860 0278,332Mixed
T. Rowe Price728,2820 00For
TOUCHSTONE FUNDS GROUP TRUST660,3160 00For
TIAA622,8500 00For
AQR580,9410 00For
Charles Schwab557,6160 00For
John Hancock410,0480 00For
AMG FUNDS288,5380 00For
MFS257,0570 00For
Invesco221,5010 00For
Nationwide113,7880 00For
FRANKLIN STRATEGIC SERIES108,0670 00For
ALGER FUNDS107,1430 00For
Russell Investments96,6460 00For
MASTER INVESTMENT PORTFOLIO94,3620 00For
Goldman Sachs85,9250 00For
Harbor ETF Trust83,6560 00For
RBB FUND, INC.80,2810 00For
Direxion Shares ETF Trust76,7850 00For
ProShares76,5530 00For
Delaware/Macquarie76,5310 00For
Bridge Builder Trust61,3200 00For

Showing the 25 largest of 84 asset managers. All 84 are in the interactive database (link above).

Elect Director: Shehnaaz Suliman, M.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%
FOR: 65,801,638WITHHELD: 7,772,860
Details: description as filed, official tally, votes by 84 asset managers

Description as filed by funds: Nominees: Shehnaaz Suliman, M.D.

Ultragenyx Pharmaceutical Inc.’s own tally for this item (“Elect Director: Shehnaaz Suliman, M.D.”): 65,801,638 for, 7,772,860 withheld, per its Form 8-K filed May 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 89% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 84 asset managers below reported 22,056,043 for, 3,711,420 withheld, 15 abstained.

FORWITHHOLD
FOR: 22,056,043ABSTAIN: 15WITHHOLD: 3,711,420
Largest asset managers voting on “Nominees: Shehnaaz Suliman, M.D.” at Ultragenyx Pharmaceutical Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard10,720,7020 1512,940For
State Street6,3310 03,362,939Withhold
BlackRock2,754,3220 00For
Fidelity2,202,3860 0278,332Mixed
T. Rowe Price728,2820 00For
TOUCHSTONE FUNDS GROUP TRUST660,3160 00For
TIAA622,8500 00For
AQR580,9410 00For
Charles Schwab557,6160 00For
John Hancock410,0480 00For
AMG FUNDS288,5380 00For
MFS257,0570 00For
Invesco221,5010 00For
Nationwide113,7880 00For
FRANKLIN STRATEGIC SERIES108,0670 00For
ALGER FUNDS107,1430 00For
Russell Investments96,6460 00For
MASTER INVESTMENT PORTFOLIO94,3620 00For
Goldman Sachs85,9250 00For
Harbor ETF Trust83,6560 00For
RBB FUND, INC.80,2810 00For
Direxion Shares ETF Trust76,7850 00For
ProShares76,5530 00For
Delaware/Macquarie76,5310 00For
Bridge Builder Trust61,3200 00For

Showing the 25 largest of 84 asset managers. All 84 are in the interactive database (link above).

Approval of the Third A&R 2023 Plan At the Annual Meeting, the Company's stockholders approved the Third A&R 2023 Plan…

Official resultCOMPENSATIONReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

69% Approved · of votes cast

FOR 69%AGAINST
FOR: 50,659,150AGAINST: 22,888,600
Details: description as filed, official tally, votes by 86 asset managers

Description as filed by funds: Approval of the Third Amended and Restated 2023 Incentive Plan.

Ultragenyx Pharmaceutical Inc.’s own tally for this item (“Proposal 2: Approval of the Third A&R 2023 Plan At the Annual Meeting, the Company's stockholders approved the Third A&R 2023 Plan. The votes on Proposal 2 were as follows:”): 50,659,150 for, 22,888,600 against — passed, per its Form 8-K filed May 18, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal No. 2 – Approval of the Third A&R 2023 Plan At the Annual Meeting, the Company's stockholders approved the Third A&R 2023 Plan.”
Support: 69% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 86 asset managers below reported 22,063,488 for, 3,698,928 against, 6,276 abstained.

FORAGAINST
FOR: 22,063,488AGAINST: 3,698,928ABSTAIN: 6,276
Largest asset managers voting on “Approval of the Third Amended and Restated 2023 Incentive Plan.” at Ultragenyx Pharmaceutical Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard10,713,28920,368 00For
State Street3,360,3408,930 00For
BlackRock2,754,3220 00For
Fidelity1,674,115806,603 00Mixed
T. Rowe Price728,2820 00For
TOUCHSTONE FUNDS GROUP TRUST660,3160 00For
TIAA0622,850 00Against
AQR0580,941 00Against
Charles Schwab557,6160 00For
John Hancock6,718403,330 00Against
AMG FUNDS0288,538 00Against
MFS257,0570 00For
Invesco221,5010 00For
Nationwide0113,788 00Against
FRANKLIN STRATEGIC SERIES108,0670 00For
ALGER FUNDS0107,143 00Against
Russell Investments96,6460 00For
MASTER INVESTMENT PORTFOLIO94,3620 00For
Goldman Sachs65,15720,768 00Mixed
Harbor ETF Trust83,6560 00For
RBB FUND, INC.80,2810 00For
Direxion Shares ETF Trust076,785 00Against
ProShares076,553 00Against
Delaware/Macquarie076,531 00Against
Bridge Builder Trust61,3200 00For

Showing the 25 largest of 86 asset managers. All 86 are in the interactive database (link above).

Advisory (Non-Binding) Vote to Approve Executive Compensation At the Annual Meeting, the Company's stockholders voted…

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Combines 6 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 70,945,277AGAINST: 2,594,517

Prior year: 67.9% for (May 15, 2025 meeting) ▲ 28.6 pts

Details: description as filed, official tally, votes by 318 asset managers

Description as filed by funds: Advisory (non-binding) vote to approve the compensation of our named executive officers.

Ultragenyx Pharmaceutical Inc.’s own tally for this item (“4. Advisory (Non-Binding) Vote to Approve Executive Compensation At the Annual Meeting, the Company's stockholders voted, on an advisory basis, in favor of a resolution approving the compensation the Company pays to its ”): 70,945,277 for, 2,594,517 against, per its Form 8-K filed May 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 83 asset managers voting on “Advisory (non-binding) vote to approve the compensation of our named executive officers.” at Ultragenyx Pharmaceutical Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard10,725,4318,226 00For
State Street3,364,3374,933 00For
BlackRock2,754,3220 00For
Fidelity2,480,7180 00For
T. Rowe Price728,2820 00For
TOUCHSTONE FUNDS GROUP TRUST660,3160 00For
TIAA622,8500 00For
AQR580,9410 00For
Charles Schwab557,6160 00For
John Hancock410,0480 00For
AMG FUNDS288,5380 00For
MFS257,0570 00For
Invesco221,5010 00For
Nationwide113,7880 00For
FRANKLIN STRATEGIC SERIES108,0670 00For
ALGER FUNDS107,1430 00For
Russell Investments96,6460 00For
MASTER INVESTMENT PORTFOLIO94,3620 00For
Goldman Sachs85,9250 00For
Harbor ETF Trust83,6560 00For
RBB FUND, INC.80,2810 00For
Direxion Shares ETF Trust76,7850 00For
ProShares76,5530 00For
Delaware/Macquarie76,5310 00For
Bridge Builder Trust61,3200 00For

Fund voting reports, all 83 managers: 25,650,442 for, 110,720 against, 6,276 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 249 asset managers voting on “Advisory (non-binding) vote to approve the compensation of our named executive officers.” at Ultragenyx Pharmaceutical Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
State Street4,780,6348,499 00For
BlackRock3,731,7670 00For
RTW INVESTMENTS, LP3,648,7950 00For
SANDS CAPITAL MANAGEMENT, LLC2,150,0830 00For
Wellington1,995,9500 00For
GEODE CAPITAL MANAGEMENT, LLC1,806,9030 00For
GW&K Investment Management, LLC538,0390 00For
AQR1,405,7990 00For
Rock Springs Capital Management LP1,199,7690 00For
T. Rowe Price1,169,2550 00For
Sofinnova Investments, Inc.1,116,2530 00For
Candriam S.C.A.1,096,1820 00For
FRONTIER CAPITAL MANAGEMENT CO LLC1,026,6070 00For
Two Sigma1,011,6520 00For
DE Shaw1,005,9940 00For
Citadel992,0360 00For
Catalio Capital Management, LP825,6240 00For
Vanguard752,2100 00For
JACOBS LEVY EQUITY MANAGEMENT, INC714,3440 00For
Nuveen654,5990 00For
BNP Paribas Asset Management Holding S.A.0639,441 00Against
PICTET ASSET MANAGEMENT SA582,5210 00For
Charles Schwab557,6660 00For
Northern Trust515,2200 00For
Eagle Health Investments LP480,7710 00For

Institutional-manager reports, all 249 managers: 41,557,136 for, 1,663,313 against, 284 not voted, 933,319 mixed. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of Selection of Independent Registered Accounting Firm At the Annual Meeting, the Company's stockholders…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

99.7% Approved · of votes cast

FOR 99.7%
FOR: 84,551,399AGAINST: 221,802

Prior year: 97.5% for (May 15, 2025 meeting) ▲ 2.3 pts

Details: description as filed, official tally, votes by 84 asset managers

Description as filed by funds: Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.

Ultragenyx Pharmaceutical Inc.’s own tally for this item (“Proposal 3: Ratification of Selection of Independent Registered Accounting Firm At the Annual Meeting, the Company's stockholders ratified the selection of Ernst & Young LLP as the independent registered public accountin”): 84,551,399 for, 221,802 against — passed, per its Form 8-K filed May 18, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal No. 3 – Ratification of Selection of Independent Registered Accounting Firm At the Annual Meeting, the Company's stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026.”
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 84 asset managers below reported 25,761,069 for, 134 against, 6,276 abstained.

FOR
FOR: 25,761,069AGAINST: 134ABSTAIN: 6,276
Largest asset managers voting on “Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for th” at Ultragenyx Pharmaceutical Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard10,733,6570 00For
State Street3,369,136134 00For
BlackRock2,754,3220 00For
Fidelity2,480,7180 00For
T. Rowe Price728,2820 00For
TOUCHSTONE FUNDS GROUP TRUST660,3160 00For
TIAA622,8500 00For
AQR580,9410 00For
Charles Schwab557,6160 00For
John Hancock410,0480 00For
AMG FUNDS288,5380 00For
MFS257,0570 00For
Invesco221,5010 00For
Nationwide113,7880 00For
FRANKLIN STRATEGIC SERIES108,0670 00For
ALGER FUNDS107,1430 00For
Russell Investments96,6460 00For
MASTER INVESTMENT PORTFOLIO94,3620 00For
Goldman Sachs85,9250 00For
Harbor ETF Trust83,6560 00For
RBB FUND, INC.80,2810 00For
Direxion Shares ETF Trust76,7850 00For
ProShares76,5530 00For
Delaware/Macquarie76,5310 00For
Bridge Builder Trust61,3200 00For

Showing the 25 largest of 84 asset managers. All 84 are in the interactive database (link above).

Largest Ultragenyx Pharmaceutical Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 98,300,000 shares outstanding at the time of that meeting.

Fund voting reports: top Ultragenyx Pharmaceutical Inc. shareholders by shares voted on “Advisory (non-binding) vote to approve the compensation of our named executive officers.”, 2025-2026
#Asset manager % of shares outstanding
1Vanguard 10.92%
2State Street 3.43%
3BlackRock 2.80%
4Fidelity 2.52%
5T. Rowe Price 0.74%
6TOUCHSTONE FUNDS GROUP TRUST 0.67%
7TIAA 0.63%
8AQR 0.59%
9Charles Schwab 0.57%
10John Hancock 0.42%
Institutional-manager reports: top Ultragenyx Pharmaceutical Inc. shareholders by shares voted on “Advisory (non-binding) vote to approve the compensation of our named executive officers.”, 2025-2026
#Asset manager % of shares outstanding
1State Street 4.87%
2BlackRock 3.80%
3RTW INVESTMENTS, LP 3.71%
4SANDS CAPITAL MANAGEMENT, LLC 2.19%
5Wellington 2.03%
6GEODE CAPITAL MANAGEMENT, LLC 1.84%
7GW&K Investment Management, LLC 1.50%
8AQR 1.43%
9Rock Springs Capital Management LP 1.22%
10T. Rowe Price 1.19%

Reported Ultragenyx Pharmaceutical Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Ultragenyx Pharmaceutical Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
RTW Investments, LP7,796,895 7.93%Schedule 13G, filed August 14, 2026
BlackRock7,299,598 7.43%Form 13F, quarter ended March 31, 2026
Vanguard Portfolio Management6,853,427 6.97%Schedule 13G, filed July 31, 2026
State Street5,021,441 5.11%Form 13F, quarter ended March 31, 2026
AQR Capital4,578,024 4.66%Form 13F, quarter ended March 31, 2026
FMR LLC3,347,890 3.41%Schedule 13G, filed February 5, 2026
Wellington Management2,640,812 2.69%Form 13F, quarter ended March 31, 2026
Citadel Advisors2,371,391 2.41%Form 13F, quarter ended March 31, 2026
Two Sigma2,205,820 2.24%Form 13F, quarter ended March 31, 2026
Morgan Stanley1,826,295 1.86%Form 13F, quarter ended March 31, 2026

Percentages above are of 98,300,000 shares outstanding, as reported by Ultragenyx Pharmaceutical Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Ultragenyx Pharmaceutical Inc.'s shareholder meeting held May 14, 2026, in the 2025-2026 proxy season, 318 asset managers reported votes on at least one of its 6 ballot items in their SEC Form N-PX filings, covering 1,957 separate fund positions. On the most widely held item on that ballot — Advisory (non-binding) vote to approve the compensation of our named executive officers. — FOR was 96% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Ultragenyx Pharmaceutical Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 18, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Ultragenyx Pharmaceutical Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Ultragenyx Pharmaceutical Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Ultragenyx Pharmaceutical (RARE) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/ultragenyx-pharmaceutical-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.